Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Marc Tessier-Lavigne
Biotech
Xaira, Anthos, CureVac & more—Chutes & Ladders
Ousted former Stanford president to lead new billion-dollar biotech. Fresh off BMS buy, Karuna’s ex-CEO to helm Anthos. CureVac names new CBO.
Max Bayer
,
Gabrielle Masson
,
Andrea Park
Apr 26, 2024 8:30am
New AI drug discovery powerhouse Xaira rises with $1B in funding
Apr 24, 2024 6:00am
Stanford president resigns—Chutes & Ladders
Jul 21, 2023 9:30am
Genentech probe of Tessier-Lavigne paper finds no fraud evidence
Apr 7, 2023 8:30am
Biotech execs head to White House meeting against backdrop of Trump cuts
May 8, 2017 7:24am
